Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Mar 29;16(1):422.
doi: 10.1007/s12672-025-02062-9.

Nanotechnology-based drug delivery system for the diagnosis and treatment of ovarian cancer

Rajeswari Saripilli  1 , Dinesh Kumar Sharma  2
Affiliations
Review

Nanotechnology-based drug delivery system for the diagnosis and treatment of ovarian cancer

Rajeswari Saripilli et al. Discov Oncol. .

Abstract

Current research in nanotechnology is improving or developing novel applications that could improve disease diagnosis or treatment. This study highlights several nanoscale drug delivery technologies, such as nano micelles, nanocapsules, nanoparticles, liposomes, branching dendrimers, and nanostructured lipid formulations for the targeted therapy of ovarian cancer (OC), to overcome the limitations of traditional delivery. Because traditional drug delivery to malignant cells has intrinsic flaws, new nanotechnological-based treatments have been developed to address these conditions. Ovarian cancer is the most common gynecological cancer and has a higher death rate because of its late diagnosis and recurrence. This review emphasizes the discipline of medical nanotechnology, which has made great strides in recent years to solve current issues and enhance the detection and treatment of many diseases, including cancer. This system has the potential to provide real-time monitoring and diagnostics for ovarian cancer treatment, as well as simultaneous delivery of therapeutic agents.

Keywords: Anticancer drug; Drug delivery; Drug targeting; Nanotechnology; Ovarian cancer.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Schematic representation of nanotechnology techniques for the diagnosis and treatment of ovarian cancer
Fig. 2
Fig. 2
Nanotechnology-based drug delivery systems for the treatment of ovarian cancer
Fig. 3
Fig. 3
Targeted drug delivery of nanoparticles-loaded with anticancer drug for the treatment of ovarian cancer
Fig. 4
Fig. 4
Graphical illustration of nanocarriers used in ovarian cancer treatment, their mechanisms, and clinical outcomes
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ziller C, Lincet H, Muller CD, Staedel C, Behr JP, Poulain L. The cyclin-dependent kinase inhibitor p21cip1/waf1 enhances the cytotoxicity of ganciclovir in HSV-tk transfected ovarian carcinoma cells. Cancer Lett. 2004;212(1):43–52. 10.1016/j.canlet.2004.03.048. - PubMed
    1. Eishi A, Rahimi E, Akhavan S, Shahgaibi S, Fariba F. Cancer during pregnancy: a review of 10 years of experience. Pak J Biol Sci. 2012;15(7):341–6. 10.3923/pjbs.2012.341.346. - PubMed
    1. Gidwani B, Vyas A. The potentials of nanotechnology-based drug delivery system for treatment of ovarian cancer. Artif Cells Nanomed Biotechnol. 2015;43(4):291–7. 10.3109/21691401.2013.853179. - PubMed
    1. Satpathy M, Wang L, Zielinski RJ, Qian W, Wang YA, Mohs AM, Kairdolf BA, Ji X, Capala J, Lipowska M, Nie S. Targeted drug delivery and image-guided therapy of heterogeneous ovarian cancer using HER2-targeted theranostic nanoparticles. Theranostics. 2019;9(3):778–95. 10.7150/thno.29964. - PMC - PubMed
    1. Talluri S, Malla RR. Superparamagnetic iron oxide nanoparticles (SPIONs) for diagnosis and treatment of breast, ovarian and cervical cancers. Curr Drug Metab. 2019;20(12):942–5. 10.2174/1389200220666191016124958. - PubMed

LinkOut - more resources